Recipient ABCB1, donor and recipient CYP3A5 genotypes influence tacrolimus pharmacokinetics in liver transplant cases-Science-Chemical Encyclopedia-lookchem

Recipient ABCB1, donor and recipient CYP3A5 genotypes influence TACROLIMUS (cas 109581-93-3) pharmacokinetics in liver transplant cases
Add time:07/28/2019 Source:sciencedirect.com

BackgroundEffective immunosuppression through optimization of trough levels TACROLIMUS (cas 109581-93-3) reduces post-transplant mortality rate in liver transplant cases.

We also recommend Trading Suppliers and Manufacturers of TACROLIMUS (cas 109581-93-3). Pls Click Website Link as below: cas 109581-93-3 suppliers

Prev:Inhibitory effect of immunosuppressive drug TACROLIMUS (cas 109581-93-3) on voltage-gated K+ current in rabbit coronary arterial smooth muscle cells
Next: Relationships between concomitant biologic DMARDs and prednisolone administration and blood TACROLIMUS (cas 109581-93-3) exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients)

Encyclopedia